Cargando…

Antibody-Drug Conjugates: The New Frontier of Chemotherapy

In recent years, antibody-drug conjugates (ADCs) have become promising antitumor agents to be used as one of the tools in personalized cancer medicine. ADCs are comprised of a drug with cytotoxic activity cross-linked to a monoclonal antibody, targeting antigens expressed at higher levels on tumor c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ponziani, Sara, Di Vittorio, Giulia, Pitari, Giuseppina, Cimini, Anna Maria, Ardini, Matteo, Gentile, Roberta, Iacobelli, Stefano, Sala, Gianluca, Capone, Emily, Flavell, David J., Ippoliti, Rodolfo, Giansanti, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432430/ https://www.ncbi.nlm.nih.gov/pubmed/32752132 http://dx.doi.org/10.3390/ijms21155510

Ejemplares similares

Recent Advances on Affibody- and DARPin-Conjugated Nanomaterials in Cancer Therapy
por: Gabriele, Federica, et al.
Publicado: (2023)

EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma
por: Capone, Emily, et al.
Publicado: (2017)

Extracellular LGALS3BP: a potential disease marker and actionable target for antibody–drug conjugate therapy in glioblastoma
por: Dufrusine, Beatrice, et al.
Publicado: (2023)

Aptamer-Driven Toxin Gene Delivery in U87 Model Glioblastoma Cells
por: di Leandro, Luana, et al.
Publicado: (2021)

Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma
por: Capone, Emily, et al.
Publicado: (2020)

Taking Advantage of the Morpheein Behavior of Peroxiredoxin in Bionanotechnology
por: Ardini, Matteo, et al.
Publicado: (2021)

Bio-Tailored Sensing at the Nanoscale: Biochemical Aspects and Applications
por: Fata, Francesca, et al.
Publicado: (2023)

Neuronal Cells Rearrangement During Aging and Neurodegenerative Disease: Metabolism, Oxidative Stress and Organelles Dynamic
por: Castelli, Vanessa, et al.
Publicado: (2019)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma
por: Capone, Emily, et al.
Publicado: (2017)

Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target
por: Capone, Emily, et al.
Publicado: (2021)

Corrigendum: Theranostic Nanomedicine for Malignant Gliomas
por: d'Angelo, Michele, et al.
Publicado: (2020)

Theranostic Nanomedicine for Malignant Gliomas
por: d'Angelo, Michele, et al.
Publicado: (2019)

Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins
por: Giansanti, Francesco, et al.
Publicado: (2018)

From Immunotoxins to Suicide Toxin Delivery Approaches: Is There a Clinical Opportunity?
por: Ardini, Matteo, et al.
Publicado: (2022)

Visualizing Galectin-3 Binding Protein Expression with ImmunoPET
por: Keinänen, Outi, et al.
Publicado: (2023)

EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors
por: Capone, Emily, et al.
Publicado: (2021)

Innovative Therapies against Human Glioblastoma Multiforme
por: Cimini, Annamaria, et al.
Publicado: (2011)

Optimization of construct design and fermentation strategy for the production of bioactive ATF-SAP, a saporin based anti-tumoral uPAR-targeted chimera
por: Errico Provenzano, Alfredo, et al.
Publicado: (2016)

Scientific Research in Homeopathic Medicine: Validation, Methodology and Perspectives
por: Pitari, Giuseppina
Publicado: (2007)

Increased Gal-3BP plasma levels in hospitalized patients infected with SARS-CoV-2
por: Gallo, Valentina, et al.
Publicado: (2022)

A special collection of reviews on frontiers in immunology
por: Xu, Chenqi, et al.
Publicado: (2020)

Probiotic DSF counteracts chemotherapy induced neuropathic pain
por: Castelli, Vanessa, et al.
Publicado: (2018)

Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems
por: Della Cristina, Pietro, et al.
Publicado: (2015)

Galectin-3 binding protein stimulated IL-6 expression is impeded by antibody intervention in SARS-CoV-2 susceptible cell lines
por: Mendes-Frias, Ana, et al.
Publicado: (2022)

ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs)
por: Prasetyanti, Pramudita R., et al.
Publicado: (2015)

Antiviral chemotherapy--a frontier for health and learning.
por: Jackson, G. G.
Publicado: (1982)

Bacterial Protein Interaction Networks: Connectivity is Ruled by Gene Conservation, Essentiality and Function
por: Dilucca, Maddalena, et al.
Publicado: (2021)

Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers
por: Cerrito, Lucia, et al.
Publicado: (2019)

Editorial: Frontiers in Hemoglobinopathies: New Insights and Methods
por: Risoluti, Roberta, et al.
Publicado: (2021)

Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review
por: Perrotti, Vittoria, et al.
Publicado: (2021)

Frontier Detectors for Frontier Physics: 13th Pisa Meeting on Advanced Detectors
por: Bisogni, Maria Giuseppina, et al.
Publicado: (2016)

Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer
por: Emmanouilidi, Aikaterini, et al.
Publicado: (2019)

Point-of-care devices: the next frontier in personalized chemotherapy
por: Borba, Maria Amélia Carlos Souto Maior, et al.
Publicado: (2017)

HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target
por: Capone, Emily, et al.
Publicado: (2023)

Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer
por: Ghasemi, R, et al.
Publicado: (2014)

Metal‐based nanomaterials and nanocomposites as promising frontier in cancer chemotherapy
por: Kumar, Sunil, et al.
Publicado: (2023)

Neuroprotective effects of the PPARβ/δ antagonist GSK0660 in in vitro and in vivo Parkinson’s disease models
por: Antonosante, Andrea, et al.
Publicado: (2023)

PPARγ and Cognitive Performance
por: d’Angelo, Michele, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?
por: Modena, Alessandra, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_im0r1qanfmlk93bvh4roql2qi0